Therapeutic blockage of the PD-1/PD-L1 checkpoint has proven significant clinical benefit in many advanced solid malignancies like melanoma and non-small cell lung cancers and opened a new era of precision cancer medicine [10,11,12]. This evidence concerns the gene PDCD1 and melanoma.